Caduet is a drug owned by Pharmacia And Upjohn Co Llc. It is protected by 7 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 11, 2018. Details of Caduet's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6455574 | Therapeutic combination |
Aug, 2018
(6 years ago) |
Expired
|
|
US5969156 (Pediatric) | Crystalline [R- (R*,R*)]-2-(4-Dfluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)- 3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) |
Jan, 2017
(7 years ago) |
Expired
|
| US5969156 | Crystalline [R- (R*,R*)]-2-(4-Dfluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)- 3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) |
Jul, 2016
(8 years ago) |
Expired
|
|
US5686104 (Pediatric) | Stable oral CI-981 formulation and process of preparing same |
May, 2015
(9 years ago) |
Expired
|
| US5686104 | Stable oral CI-981 formulation and process of preparing same |
Nov, 2014
(10 years ago) |
Expired
|
|
US6126971 (Pediatric) | Stable oral CI-981 formulation and process for preparing same |
Jul, 2013
(11 years ago) |
Expired
|
| US6126971 | Stable oral CI-981 formulation and process for preparing same |
Jan, 2013
(11 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Caduet is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Caduet's family patents as well as insights into ongoing legal events on those patents.
Caduet's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Caduet's generic launch date based on the expiry of its last outstanding patent is estimated to be Aug 11, 2018 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Caduet Generic API suppliers:
Amlodipine Besylate; Atorvastatin Calcium is the generic name for the brand Caduet. 4 different companies have already filed for the generic of Caduet, with Dr Reddys having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Caduet's generic
How can I launch a generic of Caduet before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Caduet's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Caduet's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Caduet -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 2.5 mg/10 mg 2.5 mg/20 mg 10 mg/40 mg | 17 Sep, 2009 | 1 | 29 Nov, 2013 | 11 Aug, 2018 | Extinguished |
| 2.5 mg/40 mg | 17 Sep, 2009 | 1 | 29 Nov, 2013 | 11 Aug, 2018 | Extinguished |
| 5 mg/10 mg 5 mg/20 mg 5 mg/40 mg 10 mg/10 mg 10 mg/20 mg 10 mg/80 mg | 29 Dec, 2006 | 1 | 11 Aug, 2018 | Extinguished | |
| 5 mg/80 mg | 07 Apr, 2009 | 1 | 11 Aug, 2018 | Extinguished |
Alternative Brands for Caduet
Caduet which is used for treating hypercholesterolemia, hyperlipidemia, and hypertension., has several other brand drugs in the same treatment category . Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Upjohn |
| |||
About Caduet
Caduet is a drug owned by Pharmacia And Upjohn Co Llc. It is used for treating hypercholesterolemia, hyperlipidemia, and hypertension. Caduet uses Amlodipine Besylate; Atorvastatin Calcium as an active ingredient. Caduet was launched by Pharmacia in 2004.
Approval Date:
Caduet was approved by FDA for market use on 29 July, 2004.
Active Ingredient:
Caduet uses Amlodipine Besylate; Atorvastatin Calcium as the active ingredient. Check out other Drugs and Companies using Amlodipine Besylate; Atorvastatin Calcium ingredient
Treatment:
Caduet is used for treating hypercholesterolemia, hyperlipidemia, and hypertension.
Dosage:
Caduet is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 10MG BASE;EQ 40MG BASE | TABLET | Prescription | ORAL |
| EQ 5MG BASE;EQ 40MG BASE | TABLET | Prescription | ORAL |
| EQ 5MG BASE;EQ 10MG BASE | TABLET | Prescription | ORAL |
| EQ 10MG BASE;EQ 20MG BASE | TABLET | Prescription | ORAL |
| EQ 5MG BASE;EQ 80MG BASE | TABLET | Prescription | ORAL |
| EQ 5MG BASE;EQ 20MG BASE | TABLET | Prescription | ORAL |
| EQ 10MG BASE;EQ 80MG BASE | TABLET | Prescription | ORAL |
| EQ 10MG BASE;EQ 10MG BASE | TABLET | Prescription | ORAL |
| EQ 2.5MG BASE;EQ 40MG BASE | TABLET | Prescription | ORAL |
| EQ 2.5MG BASE;EQ 20MG BASE | TABLET | Prescription | ORAL |
| EQ 2.5MG BASE;EQ 10MG BASE | TABLET | Prescription | ORAL |